DCTPep ID  DCTPep01277

Peptide Name   Sequence 20 from Patent US 20060122119

Sequence  PLDCVLYRY

Sequence Length  9

UniProt ID  P40967  Q06154  Q60696 

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

PDB ID  Not available

Predicted Structure  Not available

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L

Grand average of hydropathicity (GRAVY)  0.233

Half Life 
  >20 hours (mammalian reticulocytes, in vitro).
  >20 hours (yeast, in vivo).
  ? (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 2980
  Abs 0.1% (=1 g/l) 2.611, assuming all pairs of Cys residues form cystines
  Ext. coefficient 2980
  Abs 0.1% (=1 g/l) 2.611, assuming all Cys residues are reduced

Amino acid distribution

Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2006/0122119 A1

Patent Title  Peptides for use in antitumor immunotherapy.

Other Iinformation  Granted Patent Family: 10s / 10ex; Family Jurisdictions: CA, AU, FR, WO, US, EP, JP; Legal Status: Discontinued; Application No: 50633405; Filed:May 25, 2005; Published: Jun 8, 2006; Earliest Priority: Mar 4, 2002

Other Published ID  CA2477762A1  EP1481009A2  WO2003074565A2  WO2003074565A3